Investigators compared risk prediction using PathomIQ's platform to molecular test results, evaluating its ability to predict biochemical recurrence in high-risk patients.

Health Canada has allowed the firm to bypass a requirement that tests be authorized for non-professional use prior to self-test authorization.

Last week, readers were most interested in a story about Diasorin's submission to FDA for its POC testing instrument.

The Tulane team has developed a handful of other assays for TB detection, including a mass spec test for paucibacillary TB ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

The Glasgow, Scotland-based firm's Panaromic Platform uses an infrared spectroscopy-based test with machine learning-developed algorithms to detect signals of cancer.

A lab owner, marketing firm owner, and doctor have been sentenced to between 13 months and five years in prison for their roles in a multimillion-dollar lab fraud scheme.

Lund, Sweden-based Qlucore aims to have bladder cancer and AML tests available for clinical use in Europe by 2027.

The firm is seeking marketing clearance for its Liaison NES real-time PCR instrument along with a multiplex test for flu A/B, COVID-19, and respiratory syncytial virus infection.